# Abbelight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abbelight

- Industry: Biotechnology
- Headquarters: Cachan, France
- Website: www.abbelight.com
- Total disclosed funding: $104M
- Latest round: Series B (Jan 8, 2026)
- Investors on record: 3

## About

Based in France, Abbelight SAS develops advanced imaging solutions that enhance research capabilities through innovative microscopy and nanoscopy technologies.Founded in 2016 in Cachan, France, Abbelight SAS specializes in imaging solutions designed for micro and nano-scale analysis. The company has successfully raised USD 100.00 mn in Series B funding on January 8, 2026, led by Avant Bio. Abbelight has completed one deal to date.Abbelight specializes in advanced imaging solutions that bridge the gap between microscopy and nanoscopy. Their core offerings include a portfolio of ready-to-use reagents and an automated instrument designed for reproducible workflow sample preparation. This integrated system enables users to efficiently analyze micro and nano-scale samples, addressing significant challenges in various scientific fields such as biophysics, microbiology, neuroscience, cell biology, and genomics. The products are particularly beneficial for researchers working with extracellular vesicles and nanoparticles, as well as those conducting multi-color imaging studies. Abbelight's solutions are marketed to a global customer base, with systems installed in over 100 locations worldwide, serving more than 200 users across North America, Europe, and Asia.Abbelight generates revenue through direct sales of its imaging systems, sample preparation reagents, and data analysis software, specifically the Abbelight™ SAFe platform. The company engages in B2B transactions, primarily targeting academic institutions and research laboratories that require advanced imaging technologies. Clients typically purchase Abbelight's products as part of comprehensive workflow solutions that include both hardware and software, enhancing their research capabilities. Revenue is structured around one-time product sales, supplemented by potential service agreements for support and maintenance, with pricing plans aligned with the needs of research institutions.In January 2026, Abbelight SAS raised USD 100.00 mn in Series B funding, led by Avant Bio. The funds will be utilized to support the scaling of growth and further development of their imaging innovation services. The company aims to expand its product range with new offerings set for launch in the near future, while also targeting new markets, specifically in Asia and North America, to broaden their research capabilities. These strategic initiatives are expected to enhance Abbelight's market presence and operational capacity.

## Funding rounds

- Series B, Jan 8, 2026, $100M — Avant Bio
- Series B, Apr 18, 2023, $3.8M — Odyssee Venture, European Innovation Council

## Investors

- Odyssee Venture (https://capitalatlas.ai/funds/odyssee-venture) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Avant Bio (https://capitalatlas.ai/funds/avant-bio) — Series B